1. Home
  2. CDT vs BJDX Comparison

CDT vs BJDX Comparison

Compare CDT & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDT
  • BJDX
  • Stock Information
  • Founded
  • CDT 2019
  • BJDX 2015
  • Country
  • CDT United States
  • BJDX United States
  • Employees
  • CDT N/A
  • BJDX N/A
  • Industry
  • CDT Biotechnology: Pharmaceutical Preparations
  • BJDX Medical Specialities
  • Sector
  • CDT Health Care
  • BJDX Health Care
  • Exchange
  • CDT Nasdaq
  • BJDX Nasdaq
  • Market Cap
  • CDT 4.2M
  • BJDX 3.9M
  • IPO Year
  • CDT N/A
  • BJDX 2021
  • Fundamental
  • Price
  • CDT $2.84
  • BJDX $1.97
  • Analyst Decision
  • CDT
  • BJDX
  • Analyst Count
  • CDT 0
  • BJDX 0
  • Target Price
  • CDT N/A
  • BJDX N/A
  • AVG Volume (30 Days)
  • CDT 655.2K
  • BJDX 7.8M
  • Earning Date
  • CDT 11-14-2025
  • BJDX 11-07-2025
  • Dividend Yield
  • CDT N/A
  • BJDX N/A
  • EPS Growth
  • CDT N/A
  • BJDX N/A
  • EPS
  • CDT N/A
  • BJDX N/A
  • Revenue
  • CDT N/A
  • BJDX N/A
  • Revenue This Year
  • CDT N/A
  • BJDX N/A
  • Revenue Next Year
  • CDT N/A
  • BJDX $55.56
  • P/E Ratio
  • CDT N/A
  • BJDX N/A
  • Revenue Growth
  • CDT N/A
  • BJDX N/A
  • 52 Week Low
  • CDT $2.72
  • BJDX $1.26
  • 52 Week High
  • CDT $2,198.40
  • BJDX $12.45
  • Technical
  • Relative Strength Index (RSI)
  • CDT 57.41
  • BJDX 43.06
  • Support Level
  • CDT $2.78
  • BJDX $2.17
  • Resistance Level
  • CDT $3.22
  • BJDX $2.34
  • Average True Range (ATR)
  • CDT 0.38
  • BJDX 0.26
  • MACD
  • CDT -0.07
  • BJDX -0.11
  • Stochastic Oscillator
  • CDT 6.74
  • BJDX 3.21

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

About BJDX Bluejay Diagnostics Inc.

Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from 'sample-to-result' to help medical professionals make earlier and better triage/treatment decisions.

Share on Social Networks: